Histopathological markers, such as (PD‐L1) levels in tumor tissue,18 tumor mutation burden,19 and increased CD8+ tumor‐infiltrating lymphocytes,20 are reportedly predictive of the efficacy of anti‐PD‐1/PD‐L1 therapy in NSCLC patients. This evidence concerns the gene CD8A and neoplasm.